Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

17 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-10-31

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Memantine has been approved for use in Alzheimer's disease. Its mechanism of action raises questions of whether it can also be effective for non-Alzheimer's dementias such as frontotemporal dementia (FTD), which currently has no disease-modifying treatment.

This is an open-label study to probe the effects of memantine in 15 outpatients diagnosed with FTD, as shown objectively by comparing PET scans performed before and after use of the medication. The specific type of PET scan, FDG-PET, allows the investigators to gauge the effects of memantine on cortical activity levels. The investigators hypothesize that subjects on memantine will show normalization of cortical metabolic activity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia

NCT00545974

Frontal Lobe Dementia Frontotemporal Lobe Dementia Semantic Dementia

COMPLETED PHASE4

Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease

NCT00857233

Alzheimer's Disease

TERMINATED PHASE3

Memantine and Changes of Biological Markers and Brain PET Imaging in Alzheimer's Disease

NCT00800709

Alzheimer's Disease

COMPLETED PHASE4

Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients

NCT00200538

Dementia

COMPLETED PHASE2

Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease

NCT00857649

Alzheimer's Disease

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Frontotemporal Dementia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

memantine hydrochloride

memantine hydrochloride oral tablets, 10mg po bid

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ebixa Namenda

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must meet criteria for frontotemporal lobar degeneration (FTD) by Neary et al. criteria. 28 Subjects may have either the behavioural or the aphasic variant of FTD.
* Able to undergo psychometric testing.
* Must have reliable informant with daily contact with patient
* May be taking concurrent psychotropic medications, but must be on stable dosing regimen for 3 months prior to trial enrollment
* On the basis of a physical examination, medical history (including psychiatric and neurological), and results of blood chemistry carried out at screening visit, the patient in the investigator's opinion is considered healthy.
* Signed Informed Consent must be obtained from the patient or legally responsible representative and the informant prior to initiating any study specific procedures.

Exclusion Criteria

* Complaint of recurrent or persistent dizziness or constipation
* Abnormal chemistry panel particular with respect to ruling out renal insufficiency or failure. We will exclude those patients with creatinine clearance (CLcr) \< 50ml/min, per the Sakana equations for men and women.
* Angina, myocardial infarction, severe hypertension, severe cardiac arrhythmia, unstable diabetes mellitus, or new abnormalities on EKG within the past year.
* Any current malignancy, or any clinically significant hematological, endocrine, renal, hepatic, gastrointestinal or non-dementia neurological disease. If the condition has been stable for at least the past year and is judged by the investigators not to interfere with the patient's participation in the study, the patient may be included. Basal cell carcinoma is an exception.
* Non-English speaking, as cognitive tests will be in English.
* Evidence of other neurological or psychiatric disorders which preclude diagnosis of FTD (including, but not limited to, stroke, Parkinson's disease, any psychotic disorder, severe bipolar or unipolar depression) within the past year
* Current or prior history of uncontrolled seizure disorder, due to seizures reported as adverse events with memantine.
* Patients with suspected alcohol or substance abuse within last 1 year. If past history of abuse or dependence must have been abstinent for 1 year with continuing progression of dementia despite abstinence.
* Patients with active delusions or hallucinations at the time of screening.
* Female patients who are not at least two years post-menopausal or surgically sterile. Pre-menopausal women will be excluded; because almost all women are post-menopausal at the age of onset of FTD, we do not anticipate having to exclude more than one potential subject on the basis of this one exclusion criterion.
* Use of investigational drugs or participation in another investigational drug study within 3 months of screening.
* Patients who have previously been treated with memantine or have participated in an investigational study with memantine.
* Patients with history of severe drug allergy or hypersensitivity or known hypersensitivity to amantadine or memantine.

Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No